The two hit model of acute myeloid leukemia (AML) was proposed by Gilliland, 1 based on experimental data in mouse transplantation models. While expression of an activated tyrosine kinase like FLT3 induced myeloproliferation, an additional genetic hit, for example a mutated transcription factor blocking myeloid differentiation, was necessary to cause leukemia.
JAK2 is a cytoplasmatic tyrosine-kinase critical for signal transduction of type I cytokine receptors, for example EPO-R. 2 The somatic point mutation JAK2V617F is frequently found in patients with myeloproliferative disorders, [3] [4] [5] [6] but seems to be rare in other myeloid malignancies such as myelodysplastic syndromes 7 or AML. 8 Our own unpublished data and recent publications show the coexistence of JAK2V617 and AML1-ETO in AML at a frequency of 5-6% [8] [9] [10] hypothesizing that both mutations cooperate in leukemogenesis.
For the first time, we provide clinical evidence for a sequential acquirement of the JAK2V617 mutation and AML1-ETO. The initially presented myeloproliferative syndrome (MPS) (JAK2V617F þ ) progressed into AML after acquisition of an AML1-ETO rearrangement. To our knowledge, this is also the first case of a secondary AML evolving from polycythemia vera (PV) after acquisition of an AML1-ETO rearrangement.
A Letters to the Editor 103 interphase nuclei. The presence of the AML1-ETO fusion transcript was confirmed by RT-PCR. Nucleotide sequencing showed the homozygous JAK2V617F mutation in more than 95% of PB cells. The fact that more than 95% of the patient's PB cells carry the JAK2V617F mutated allele and the presence of the AML1-ETO fusion gene could be detected in about 93% of PB cells demonstrates a big overlap of these genetic lesions. This which means that more than 90% of investigated cells must carry both alterations.
The WBC could be controlled with HU until the patient developed a myeloid blast crisis in October 2006 ( Figure 1 ). Cytogenetic analysis of PB blasts confirmed the presence of the t(8;21) as the sole microscopic genetic abnormality. AML1-ETO could be detected in 76 of 101 peripheral cells by FISH. The JAK2V617F mutation, but no other genetic alterations (NPM1, FLT3-ITD, FLT3-TKD, MLL-PTD), were found neither by FISH nor by sequencing. Immunophenotyping showed expression of myeloid markers MPO, CD13, CD33, CD65, progenitor cell antigens CD117, CD34 and cross-lineage expression of the B-lymphocyte antigen CD19.
To investigate the extent of the EPO-R expression in AML1-ETO-positive blasts, we analyzed the patient's PB. In PCR analysis, according to the material and methods described by Dunlop et al. Extensive genetic workup of patients with AML has shown that class I and II mutations coexist in distinct genetic subtypes. In patients with AML1-ETO þ AML mutations of JAK2, NRAS, KIT and FLT3ITD have been described in 6-8%. 9 Furthermore, cooperations between these mutations have been shown in mouse models such as FLT3-ITD/AML1-ETO and FLT3-ITD/ PML-RARA. 12 Similar to the cooperation of FLT3 and AML1-ETO in mice 12 the activated kinase JAK2 led to activation of STAT5 causing a myeloproliferative phenotype. 13 These findings are supported by own in vitro experiments, in which stable transfection of Ba/F3 cells with the JAK2V617F mutant and the EPO-receptor showed a much stronger activation of STAT5 compared to cells with either the EPO-R, the JAK2V617F construct or the combination of JAK2 WT with the EPO-R (Figure 3) .
Experiments of Lu et al. 2 show that the coexpression of a JAK2V617F mutation and a homodimeric type I cytokine receptor (EPO-R, TPO-R, G-CSF-R) is necessary for the malignant transformation of hematopoietic cells and the development of growth factor independent signalling via JAK2 and STAT5. Interestingly, mutations in the EPO-R leading to an impairment of JAK2 or STAT5 activation also impair growth factor independence and malignant transformation.
The fact that the EPO-receptor which can normally only be found in immature progenitors in the bone marrow of healthy individual was highly expressed in peripheral blasts and more than 95% of these cells carried the JAK2V617F mutation supports our hypothesis that a consecutively strongly activated STAT5 might have favored secondary molecular changes such as the acquisition of the AML1-ETO fusion gene.
This additional block of differentiation induced by the AML1-ETO fusion gene, either spontaneously acquired or therapyrelated by HU, was then presumably necessary to cause an accelerated phase and finally leukemia.
Schnittger et al. 10 recently detected the JAK2V617F mutation in two of three patients with therapy-related AML1-ETOpositive AML. These patients had been treated with either the therapeutic combination regimen of doxorubicine and cyclophosphamide or the combination of cisplatin, etoposide and bleomycin.
The leukemogenic potential of HU is still a subject of discussion. The leukemic potential of HU seems to be increased when combined with other myelosuppressive agents 14 or used for a long-term treatment. 15 Our patient had been treated with a monotherapy of HU for less than 6 months before the development of an acceleration phase. These facts make an impact of HU on development of an acute leukemia less probable. However, we cannot rule out the possibility that HU was involved in the rapid transformation or acquisition of the AML1-ETO fusion gene.
The role of the secondary acquirement of AML1 fusion genes has been described in some patients with CML in blast crisis (t(3;21) and t(8;21)), but not in other forms of MPS. 16 The short time interval between the appearance of the AML1-ETO fusion transcript and the transformation into AML provides evidence for the cooperation of AML1-ETO and JAK2 in leukemogenesis. The cooperation between JAK2V617F and the EPO-R leads to strong activation of STAT5 compared to cells with either the EPO-R, the JAK2V6217F construct or the combination of JAK2WT with the EPO-R.
Morphometry and mathematical modelling of the capillary-like patterns formed in vitro by bone marrow macrophages of patients with multiple myeloma Bone marrow angiogenesis is a constant hallmark of multiple myeloma (MM) progression.
1 Plasma cells are seen as primary inducers of this process because they secrete major angiogenic factors, including vascular endothelial growth factor (VEGF), fibroblast growth factor-2 and matrix metalloproteinases. Stromal cells behave as secondary inducers following recruitment and activation by plasma cells. 2 In particular, bone marrow endothelial cells from patients with multiple myeloma (MMEC) were shown to actively contribute to their own expansion and angiogenesis through an autocrine loop of growth in which VEGF is highly coexpressed with its cognate receptors. 3 The aim of the present study was to further investigate the vasculogenic potential of bone marrow multiple myeloma macrophages (MMMA) of patients with MM by testing them in vitro in the Matrigel assay and by using quantitative, morphometric methods to compare the patterns they formed with those generated by their endothelial counterpart. Moreover, a mathematical model of the self-assembly of the cells was elaborated to characterize the relationship between a set of cellular and biochemical parameters and the structure of the patterns formed by MMMA in vitro.
When seeded on Matrigel, a number of MMMA rapidly changed their morphology and developed an elongated shape. These cells appeared either as single cells or in clusters with round cells centrally and sprouts of elongated cells at the periphery. After 18 h, the formation of a pattern consisting of cord-and tubular-like structures was observed, sometimes arranged to form closed meshes. As detailed in Table 1 , the MMMA self-organization, resembling the first stages of vasculogenesis, was significantly less complex than the organization exhibited by their endothelial counterpart. The percent of area covered by the pattern was about half of that observed in endothelial cell cultures, with a lower number of meshes (2.170.6 per mm 2 ) and of branching points (5678 per mm 2 ). Figure 1 shows the results of the simulations performed by running the computational model of in vitro angiogenesis with different amounts of differentiated MA in the system. As outlined before, the biophysical parameters assumed in the simulations were consistent with the available experimental evidence. As illustrated, a good similarity between simulated and observed patterns was obtained when the percentage of differentiated
